Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders.

MedStar author(s):
Citation: Journal of Clinical Endocrinology & Metabolism. 106(1):226-236, 2021 01 01.PMID: 33159436Institution: MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment: Medicine/EndocrinologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Amiodarone/ae [Adverse Effects] | *Thyroid Diseases/ci [Chemically Induced] | *Thyroid Diseases/th [Therapy] | Albania | Arrhythmias, Cardiac/dt [Drug Therapy] | Arrhythmias, Cardiac/et [Etiology] | Coronary Artery Disease/co [Complications] | Coronary Artery Disease/dt [Drug Therapy] | Humans | Male | Middle Aged | Myocardial Infarction/co [Complications] | Myocardial Infarction/dt [Drug Therapy] | Thyroid Diseases/di [Diagnosis] | Thyroid Function TestsYear: 2021Local holdings: Available online through MWHC library: 1999- June 2013, Available in print through MWHC library: 1999 - 2006ISSN:
  • 0021-972X
Name of journal: The Journal of clinical endocrinology and metabolismAbstract: Amiodarone is a class III antiarrhythmic drug containing 37% iodine by weight, with a structure similar to that of thyroid hormones. Deiodination of amiodarone releases large amounts of iodine that can impair thyroid function, causing either hypothyroidism or thyrotoxicosis in susceptible individuals reflecting ~20% of patients administered the drug. Not only the excess iodine, but also the amiodarone (or its metabolite, desethylamiodarone) itself may cause thyroid dysfunction by direct cytotoxicity on thyroid cells. We present an overview of the epidemiology and pathophysiology of amiodarone-induced thyroid disorders, with a focus on the various forms of clinical presentation and recommendations for personalized management of each form. Copyright (c) The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected].All authors: Burman KD, Wartofsky L, Ylli DOriginally published: Journal of Clinical Endocrinology & Metabolism. 106(1):226-236, 2021 Jan 01.Fiscal year: FY2021Digital Object Identifier: Date added to catalog: 2020-12-31
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 33159436 Available 33159436

Available online through MWHC library: 1999- June 2013, Available in print through MWHC library: 1999 - 2006

Amiodarone is a class III antiarrhythmic drug containing 37% iodine by weight, with a structure similar to that of thyroid hormones. Deiodination of amiodarone releases large amounts of iodine that can impair thyroid function, causing either hypothyroidism or thyrotoxicosis in susceptible individuals reflecting ~20% of patients administered the drug. Not only the excess iodine, but also the amiodarone (or its metabolite, desethylamiodarone) itself may cause thyroid dysfunction by direct cytotoxicity on thyroid cells. We present an overview of the epidemiology and pathophysiology of amiodarone-induced thyroid disorders, with a focus on the various forms of clinical presentation and recommendations for personalized management of each form. Copyright (c) The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected].

English

Powered by Koha